Prospective GN cohorts that stratify by glycaemic exposure during steroid therapy and track podocyte biomarkers (e.g., urinary nephrin/podocin transcripts, podocyte-derived extracellular vesicles) and, when feasible, ultrastructural endpoints (electron microscopy) are warranted. This evidence concerns the gene NPHS2 and ganglioneuroma.